Why the study?
In patients undergoing cardiopulmonary bypass who develop heparin resistance after receiving andexanet alfa, the choice of alternative anticoagulants presents a clinical challenge.
Nafamostat mesilate can successfully provide anticoagulation during cardiopulmonary bypass in patients experiencing heparin resistance due to prior andexanet alfa administration.
Answers are grounded in this paper and cite their sources.
Case report of andexanet alfa in heparin-resistant CPB; hypothesis-generating, prospective data needed before any clinical consideration.
Andexanet alfa is an analog of activated factor X and is used as an antagonist of anti-activated factor X agents. Andexanet alfa is useful for hemostasis in emergent bleeding during direct oral anticoagulant administration, which contributes to safety. In patients undergoing surgery with cardiopulmonary bypass because of heparin resistance, anesthesiologists are faced with a choice of anticoagulants. Herein, we experienced anesthesia for vascular prostheses with cardiopulmonary bypass for acute aortic dissection in a patient who had received andexanet alfa preoperatively. Heparin was initially used as the anticoagulant during cardiopulmonary bypass; however, despite the administration of large doses and antithrombin III preparations, anticoagulation was insufficient. Therefore, nafamostat mesilate was administered and sufficient anticoagulation was attained. The patient completed surgery under cardiopulmonary bypass, coagulation function was recovered shortly after withdrawal, and no obvious adverse effects were observed.
No takes yet. Share an insight, caveat, or question.
Kitaura et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: